Paratek Pharmaceuticals to Report First Quarter 2017 Financial Results and Provide Update on Clinical Progress on May 4, 2017...
April 26 2017 - 7:00AM
Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical
company focused on the development and commercialization of
innovative therapies based upon tetracycline chemistry, announced
today that it will host a conference call and live audio webcast on
Thursday, May 4, 2017 at 8:30 AM ET to report first quarter 2017
financial results and provide an update on its clinical development
efforts for omadacycline for skin infections, community-acquired
bacterial pneumonia, and urinary tract infections.
The audio webcast can be accessed under "Events and
Presentations" in the Investor Relations section of the Company's
website at www.paratekpharma.com.
Domestic investors wishing to participate in the call should
dial: 877-407-0792 and international investors should dial:
201-689-8263. The conference ID is 13660676. Investors can also
access the call at
http://public.viavid.com/index.php?id=124062.
Replays of the call will be available through May 18, 2017.
Domestic investors can access the replay by dialing 844-512-2921
and international investors can access the replay by dialing
412-317-6671. The PIN code to access the replay is 13660676.
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the development and commercialization of innovative
therapies based upon its expertise in novel tetracycline chemistry.
Paratek's lead product candidate, omadacycline, is the first in a
new class of tetracyclines known as aminomethylcyclines, with
broad-spectrum activity against Gram-positive, Gram-negative and
atypical bacteria. Omadacycline is a new, once-daily oral and
intravenous broad spectrum antibiotic being developed for use as
empiric monotherapy for patients suffering from serious
community-acquired bacterial infections, such as acute bacterial
skin and skin structure infections, community-acquired bacterial
pneumonia, urinary tract infections, and other
community-acquired bacterial infections, particularly when
antibiotic resistance is of concern to prescribing
physicians. Omadacycline has been granted Qualified Infectious
Disease Product designation and Fast Track status by the U.S. Food
and Drug Administration for the target indications.
In June 2016, Paratek announced positive efficacy data in a
Phase 3 registration study in acute bacterial skin and skin
structure infections (ABSSSI) demonstrating the efficacy and
general safety and tolerability of intravenous (IV) to once-daily
oral omadacycline compared to linezolid. In April 2017,
Paratek announced positive efficacy data in a Phase 3 registration
study in community-acquired bacterial pneumonia (CABP)
demonstrating the efficacy and general safety and tolerability of
IV to once-daily oral omadacycline compared to moxifloxacin. A
Phase 3 registration study in ABSSSI comparing once-daily oral-only
dosing of omadacycline to twice-daily oral-only dosing of linezolid
was initiated in August 2016. Top-line data from this study
are expected as early as the end of June. The Company plans to
submit its new drug application (NDA) in the U.S. as early as the
first quarter of 2018 with an EMA submission later in 2018.
In addition to its Phase 3 program for omadacycline, a Phase 1B
study in uncomplicated urinary tract infections (UTI) was initiated
in May 2016 and positive top-line PK proof-of-principle data was
reported in November 2016. The Company plans to begin enrolling
patients in a proof-of-concept Phase 2 study of omadacycline in
acute pyelonephritis, the most common subset of complicated urinary
tract infections, as early as December 2017.
In October 2016, Paratek announced a research agreement with
the U.S. Department of Defense to explore the utility of
omadacycline against pathogenic agents causing infectious diseases
of public health and biodefense importance including plague and
anthrax.
Paratek's second Phase 3 product candidate, sarecycline, is a
well-tolerated, once-daily oral, narrow spectrum
tetracycline-derived antibiotic with potent anti-inflammatory
properties for the potential treatment of acne and rosacea in the
community setting. Allergan owns the U.S. rights for the
development and commercialization of sarecycline. Paratek retains
all ex-U.S. rights. Allergan and Paratek reported positive results
from two identical Phase 3 registration studies of sarecycline for
the treatment of moderate to severe acne vulgaris in March
2017. Allergan has publicly announced plans to submit an NDA
in the U.S. in the second half of 2017.
For more information, visit www.paratekpharma.com.
Forward Looking Statements
This press release contains forward-looking statements including
statements related to our overall strategy, product candidates,
clinical studies, prospects, potential and expected results,
including statements about the timing of advancing omadacycline and
otherwise preparing for clinical studies, the timing of enrollment
in our clinical studies and our reporting of the results of such
studies, the potential for omadacycline to serve as an empiric
monotherapy treatment option for patients suffering from ABSSSI,
CABP, UTI, and other bacterial infections when resistance is of
concern, the prospect of omadacycline providing broad-spectrum
activity, and our ability to obtain regulatory approval of
omadacycline. All statements, other than statements of historical
facts, included in this press release are forward-looking
statements, and are identified by words such as "advancing,"
"believe," "expect," "well positioned," "look forward,"
"anticipated," "continued," and other words and terms of similar
meaning. These forward-looking statements are based upon our
current expectations and involve substantial risks and
uncertainties. We may not actually achieve the plans, carry
out the intentions or meet the expectations or projections
disclosed in our forward-looking statements and you should not
place undue reliance on these forward-looking statements. Our
actual results and the timing of events could differ materially
from those included in such forward-looking statements as a result
of these risks and uncertainties. These and other risk
factors are discussed under "Risk Factors" and elsewhere in our
Annual Report on Form 10-K for the year ended December 31, 2016,
and our other filings with the Securities and Exchange
Commission. We expressly disclaim any obligation or
undertaking to update or revise any forward-looking statements
contained herein.
CONTACTS:
Media
Relations: |
|
Investor
Relations: |
Michael Lampe |
|
Hans Vitzthum |
(484) 575-5040 |
|
LifeSci Advisors,
LLC. |
michael@scientpr.com
|
|
212-915-2568 |
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Apr 2023 to Apr 2024